If a individual handled with diclofenac sodium extended-launch tablets has any indications or signs of anemia, monitor hemoglobin or hematocrit. A dosage adjustment could be warranted when diclofenac is administered with CYP2C9 inhibitors or inducers (see CLINICAL PHARMACOLOGY; Pharmacokinetics). Risk Variables for GI Bleeding, Ulceration, and Perforation People with a https://josephb791ikn9.blogsumer.com/profile